Leukine (sargramostim) / Partner Therap 
Welcome,         Profile    Billing    Logout  
 449 Diseases   58 Trials   58 Trials   3605 News 


«12...1213141516171819202122...2425»
  • ||||||||||  Leukine (sargramostim) / Partner Therap
    Trial primary completion date:  Study of the Safety & Efficacy of Leukine (clinicaltrials.gov) -  Feb 12, 2016   
    P2,  N=40, Recruiting, 
    N=20 --> 0 | Recruiting --> Withdrawn Trial primary completion date: Jan 2016 --> Jun 2016
  • ||||||||||  Leukine (sargramostim) / Partner Therap, Panvac-VF (falimarev/inalimarev) / Bavarian Nordic
    Combination therapy, Metastases:  PANVAC-V and PANVAC-F Vaccines Plus Sargramostim to Treat Advanced Cancer (clinicaltrials.gov) -  Feb 8, 2016   
    P1,  N=51, Active, not recruiting, 
    Trial primary completion date: Jan 2016 --> Jun 2016 Trial primary completion date: Jan 2016 --> Jan 2017
  • ||||||||||  Leukine (sargramostim) / Partner Therap, Rituxan (rituximab) / Roche
    Trial primary completion date, Combination therapy:  Rituximab Plus Sargramostim (GM-CSF) In Patients With Chronic Lymphocytic Leukemia (clinicaltrials.gov) -  Feb 3, 2016   
    P2,  N=130, Active, not recruiting, 
    Not yet recruiting --> Recruiting Trial primary completion date: Aug 2016 --> Aug 2017
  • ||||||||||  Decadron (dexamethasone) / Merck (MSD), Leukine (sargramostim) / Partner Therap
    Trial primary completion date:  Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia (clinicaltrials.gov) -  Jan 25, 2016   
    P2/3,  N=60, Recruiting, 
    Recruiting --> Active, not recruiting | Trial primary completion date: May 2016 --> May 2018 Trial primary completion date: Dec 2015 --> Jan 2017
  • ||||||||||  Leukine (sargramostim) / Partner Therap
    Enrollment open, Trial initiation date, Trial primary completion date:  GRID: GM-CSF to Decrease ICU Acquired Infections (clinicaltrials.gov) -  Jan 20, 2016   
    P3,  N=488, Recruiting, 
    Trial primary completion date: Dec 2015 --> Jan 2017 Not yet recruiting --> Recruiting | Initiation date: Mar 2015 --> Sep 2015 | Trial primary completion date: Mar 2018 --> Sep 2018
  • ||||||||||  Zeltherva (galinpepimut-S) / SELLAS Life Sciences
    Trial primary completion date:  WT1 Vaccine Treatment of Patients With Multiple Myeloma After Autologous Stem Cell Transplantation (clinicaltrials.gov) -  Jan 17, 2016   
    P=N/A,  N=20, Recruiting, 
    Not yet recruiting --> Recruiting | Initiation date: Mar 2015 --> Sep 2015 | Trial primary completion date: Mar 2018 --> Sep 2018 Trial primary completion date: Apr 2016 --> Apr 2017
  • ||||||||||  Proleukin (aldesleukin) / Merck (MSD), Novartis, Iovance Biotherap, Leukine (sargramostim) / Partner Therap, Unituxin (dinutuximab) / United Therapeutics Corp, Ohara Pharma
    New P2 trial:  NB2013-HR German (GPOH) / Dutch (DCOG) Trial (clinicaltrials.gov) -  Dec 29, 2015   
    P2,  N=36, Recruiting, 
  • ||||||||||  Leukine (sargramostim) / Partner Therap, NeuVax (nelipepimut-S) / Dr. Reddy's, Herceptin (trastuzumab) / Roche
    Trial primary completion date:  Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax (clinicaltrials.gov) -  Nov 22, 2015   
    P2,  N=300, Recruiting, 
    Trial primary completion date: Dec 2015 --> Dec 2016 Trial primary completion date: Dec 2015 --> Dec 2016
  • ||||||||||  Leukine (sargramostim) / Partner Therap
    Trial primary completion date:  Phase I/IIa Trial of Folate Binding Protein Vaccine in Ovarian Cancer (clinicaltrials.gov) -  Nov 17, 2015   
    P1/2,  N=60, Active, not recruiting, 
    Trial primary completion date: Oct 2015 --> Oct 2017 Trial primary completion date: Dec 2014 --> Dec 2016
  • ||||||||||  AE 37 / Generex, Leukine (sargramostim) / Partner Therap, GLSI-100 / Greenwich LifeSci
    Trial primary completion date:  BAMC-C.2007.098: Vaccine Therapy in Treating Patients With Breast Cancer (clinicaltrials.gov) -  Nov 17, 2015   
    P2,  N=600, Active, not recruiting, 
    Trial primary completion date: Dec 2014 --> Dec 2016 Trial primary completion date: Dec 2015 --> Dec 2016
  • ||||||||||  Targretin oral (bexarotene oral) / ReXceptor, Leukine (sargramostim) / Partner Therap
    Trial primary completion date:  Bexarotene and GM-CSF in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia (clinicaltrials.gov) -  Nov 10, 2015   
    P2,  N=26, Active, not recruiting, 
    Initiation date: Aug 2015 --> Mar 2016 | Trial primary completion date: Sep 2020 --> Mar 2021 Trial primary completion date: Jul 2015 --> Jul 2016
  • ||||||||||  Leukine (sargramostim) / Partner Therap, Neupogen (filgrastim) / Kyowa Kirin, Amgen
    Trial primary completion date:  Adoptive Immunotherapy in Relapsed Hematological Malignancy: Early GVHD Prophylaxis (clinicaltrials.gov) -  Nov 8, 2015   
    P2,  N=60, Not yet recruiting, 
    Not yet recruiting --> Recruiting Trial primary completion date: Dec 2016 --> Dec 2025
  • ||||||||||  Leukine (sargramostim) / Partner Therap, Rituxan (rituximab) / Roche
    Trial primary completion date:  Rituximab + GM-CSF in Patients With Follicular B-Cell Lymphoma (clinicaltrials.gov) -  Nov 5, 2015   
    P2,  N=42, Completed, 
    Trial primary completion date: Dec 2016 --> Dec 2025 Trial primary completion date: Sep 2013 --> Dec 2006
  • ||||||||||  Leukine (sargramostim) / Partner Therap
    Enrollment open, Trial initiation date, IO biomarker:  The Immuno-Response to Primary Cryotherapy for the Treatment of Prostate Cancer (clinicaltrials.gov) -  Oct 30, 2015   
    P1,  N=20, Recruiting, 
    Trial primary completion date: Mar 2016 --> Jun 2017 Not yet recruiting --> Recruiting | Initiation date: Dec 2015 --> Sep 2015
  • ||||||||||  Leukine (sargramostim) / Partner Therap
    Trial completion, Trial primary completion date:  Does GM-CSF Restore Neutrophil Phagocytosis in Critical Illness? (clinicaltrials.gov) -  Oct 6, 2015   
    P1/2,  N=70, Completed, 
    Recruiting --> Active, not recruiting Recruiting --> Completed | Trial primary completion date: Apr 2015 --> Jan 2015
  • ||||||||||  Leukine (sargramostim) / Partner Therap, Yervoy (ipilimumab) / BMS
    Enrollment change, Trial initiation date, Trial withdrawal:  Ipilimumab and GMCSF Immunotherapy for Prostate Cancer (clinicaltrials.gov) -  Oct 5, 2015   
    P2,  N=0, Withdrawn, 
    Recruiting --> Completed | Trial primary completion date: Apr 2015 --> Jan 2015 N=54 --> 0 | Initiation date: Mar 2015 --> Jun 2015 | Not yet recruiting --> Withdrawn